#15 Safety of HIV medications – Henry Zakumumpa

With the right care, people infected with HIV can lead long and
healthy lives. But as with any life-long medical treatment, it is
important to acknowledge and manage any side effects. Henry
Zakumumpa from Makerere University School of Public Health tells
us about the potential harms of new HIV therapies and the
challenges faced by pharmacovigilance specialists in
Uganda.

Tune in to find out:


How dolutegravir-based HIV therapies compare to earlier
regimens

How pharmacovigilance data can help shape HIV treatment
guidelines 

Why we should empower patients to share concerns about their
healthcare



Want to know more?
Hyperglycemia, insomnia and reduced libido were the
most common side effects observed by Ugandan clinicians in
patients taking dolutegravir.

Nurses are the backbone of HIV disease management in Uganda and
could play an important role in pharmacovigilance activities as
well.

Henry Zakumumpa’s research was supported by Uppsala Monitoring
Centre in collaboration with CARTA, the Consortium for Advanced
Research Training in Africa, which is working to build up
research capacity in public health.

The World Health Organization’s resources on HIV/AIDS include
easily digestible information for patients, epidemiological data
on disease spread, and current guidelines for prevention and
treatment.


For more on African and patient-centred pharmacovigilance, check
out these episodes from the Drug Safety Matters archive:


Advancing pharmacovigilance in Africa

Why we should listen to patients






Join the conversation on social mediaFollow us on
Facebook, LinkedIn, X, or Bluesky and share your thoughts about
the show with the hashtag #DrugSafetyMatters.

Got a story to share?We’re always looking for new
content and interesting people to interview. If you have a great
idea for a show, get in touch!

About UMCRead more about Uppsala Monitoring Centre
and how we work to advance medicines safety.